Table 1

Sample characteristics and PD-L1 percent positivity on immune cells

Sample typeTotal N (%)N PD-L1 positive (%, 95% CI)*
Primary tumor179 (52.6)114 (63.7%, 56.2% to 70.7%)
Metastatic lesion161 (47.4)68 (42.2%, 35.1% to 50.9%)
Sites of metastases N (% of metastatic samples) N PD-L1 positive (%, 95% CI)*
Lung16 (10.0)11 (68.8%, 41.3% to 90.0%)
Soft tissues23 (14.3)15 (65.2%, 42.7% to 83.6%)
Lymph nodes45 (28.0)23 (51.1%, 35.8% to 66.3%)
Skin21 (13.0)5 (23.8%, 8.22% to 47.2%)
Liver23 (14.3)4 (17.4%, 5.00% to 38.8%)
Bone12 (7.5)2 (16.7%, 2.10% to 48.4%)
Brain9 (5.6)5
Mediastinum4 (2.5)1
Pleura2 (1.2)0
Muscle1 (<1)0
Omentum1 (<1)1
Ovary1 (<1)0
Pelvis1 (<1)0
Retroperitoneum1 (<1)0
Adrenal gland1 (<1)1

  • *Percent positivity rates within sample type and 95% CIs are provided only for tissue sites with >10 samples.

  • PD-L1, Programmed Death Ligand 1.